Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

BACKGROUND: Previous, uncontrolled studies have suggested that first-line treatment with gefitinib would be efficacious in selected patients with non-small-cell lung cancer. METHODS: In this phase 3, open-label study, we randomly assigned previously untreated patients in East Asia who had advanced p...

Full description

Saved in:

Bibliographic Details
Main Authors:	Tony S. Mok, Yi Long Wu, Sumitra Thongprasert, Chih Hsin Yang, Da Tong Chu, Nagahiro Saijo, Patrapim Sunpaweravong, Baohui Han, Benjamin Margono, Yukito Ichinose, Yutaka Nishiwaki, Yuichiro Ohe, Jin Ji Yang, Busyamas Chewaskulyong, Haiyi Jiang, Emma L. Duffield, Claire L. Watkins, Alison A. Armour, Masahiro Fukuoka
Format:	Journal
Published:	2018
Subjects:	Medicine
Online Access:	https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=69949162760&origin=inward http://cmuir.cmu.ac.th/jspui/handle/6653943832/49303
Tags:	Add Tag No Tags, Be the first to tag this record!
Institution:	Chiang Mai University

Similar Items

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma
by: Tony S. Mok, et al.
Published: (2018)

Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC
by: Yi Long Wu, et al.
Published: (2018)

Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC
by: Yi Long Wu, et al.
Published: (2018)

Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC
by: Wu Y., et al.
Published: (2017)

Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non - small-cell lung cancer in Asia (IPASS)
by: Masahiro Fukuoka, et al.
Published: (2018)

Health-related quality-of-life in a randomized phase III first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients from Asia with advanced NSCLC (IPASS)
by: Sumitra Thongprasert, et al.
Published: (2018)

Health-related quality-of-life in a randomized phase III first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients from Asia with advanced NSCLC (IPASS)
by: Thongprasert S., et al.
Published: (2014)

Lung cancer working group report
by: Nagahiro Saijo, et al.
Published: (2018)

Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non - small-cell lung cancer in Asia (IPASS)
by: Fukuoka M., et al.
Published: (2017)

Cost-effectiveness analysis of cisplatin plus etoposide and carboplatin plus paclitaxel in a phase III randomized trial for non-small cell lung cancer
by: Sumitra Thongprasert, et al.
Published: (2018)

Tumor response and health-related quality of life in clinically selected patients from Asia with advanced non-small-cell lung cancer treated with first-line gefitinib: Post hoc analyses from the IPASS study
by: Yi Long Wu, et al.
Published: (2018)

Tumor response and health-related quality of life in clinically selected patients from Asia with advanced non-small-cell lung cancer treated with first-line gefitinib: Post hoc analyses from the IPASS study
by: Yi Long Wu, et al.
Published: (2018)

A phase II study of docetaxel and carboplatin in Thai patients with advanced non-small-cell lung cancer
by: Sumitra Thongprasert, et al.
Published: (2018)

Lung cancer response to gefitinib, then erlotinib, then gefitinib again
by: Wong, A.S., et al.
Published: (2014)

Lung cancer working group report
by: Saijo N., et al.
Published: (2017)

Tumor response and health-related quality of life in clinically selected patients from Asia with advanced non-small-cell lung cancer treated with first-line gefitinib: Post hoc analyses from the IPASS study
by: Wu Y.-L., et al.
Published: (2014)

Experience with gemcitabine and cisplatin in the therapy of inoperable and metastatic cholangiocarcinoma
by: Chalyut Charoentum, et al.
Published: (2018)

Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival
by: Chee Khoon Lee, et al.
Published: (2018)

Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival
by: Chee Khoon Lee, et al.
Published: (2018)

Rapid determination of gefitinib and its main metabolite, O-desmethyl gefitinib in human plasma using liquid chromatography-tandem mass spectrometry
by: Wang, L.-Z., et al.
Published: (2014)

Evidence for disease control with erlotinib after gefitinib failure in typical gefitinib-sensitive Asian patients with non-small cell lung cancer
by: Wong, A.S., et al.
Published: (2014)

Phase II study of 24-hour infusion of paclitaxel (Intaxel) with carboplatin in advanced non-small cell lung cancer.
by: Chaiyut Charoentum, et al.
Published: (2018)

Comparison Between Gemcitabine-Carboplatin and Combination of Gemcitabine-Carboplatin and Celecoxib in Urothelial Carcinoma Cell Apoptosis
by: Widya Sakti Pratama, et al.
Published: (2019)

Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival
by: Lee C., et al.
Published: (2017)

EFFICACY OF GEFITINIB AND ERLOTINIB IN NON-SMALL-CELL LUNG CARCINOMA
by: Afrita Amalia Laitupa, -, et al.
Published: (2019)

Cost-effectiveness analysis of cisplatin plus etoposide and carboplatin plus paclitaxel in a phase III randomized trial for non-small cell lung cancer
by: Thongprasert S., et al.
Published: (2014)

Cost-effectiveness analysis of cisplatin plus etoposide and carboplatin plus paclitaxel in a phase III randomized trial for non-small cell lung cancer
by: Thongprasert S., et al.
Published: (2014)

Inhibiting proliferation of gefitinib-resistant, non-small cell lung cancer
by: Sudo, M., et al.
Published: (2014)

Dietary counseling outcomes in locally advanced unresectable or metastatic cancer patients undergoing chemotherapy
by: Napawan Sukaraphat, et al.
Published: (2018)

Two-year outcome of concurrent chemoradiation with carboplatin with or without adjuvant carboplatin/fluorouracil in nasopharyngeal cancer: A multicenter randomized trial
by: Imjai Chitapanarux, et al.
Published: (2020)

Short-hairpin RNA library: Identification of therapeutic partners for gefitinib-resistant non-small cell lung cancer
by: Sudo M., et al.
Published: (2020)

The Differences of Apoptosis Effects Between Combination of Meloxicam with Gemcitabine-Carboplatin Chemotherapy Compared to Gemcitabine-Carboplatin Chemotherapy Alone in Urothelial Carcinoma Culture Cells
by: Ananta Cahyo Nugroho, et al.
Published: (2019)

First-line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian patients with locally advanced or metastatic non-squamous non-small cell lung cancer: A randomised, phase 3 trial
by: James Chih Hsin Yang, et al.
Published: (2018)

PERBEDAAN EFEK APOPTOSIS PEMBERIAN KOMBINASI MELOKSIKAM DAN KEMOTERAPI GEMCITABINE CARBOPLATIN DIBANDINGKAN KEMOTERAPI GEMCITABINE CARBOPLATIN PADA SEL KULTUR KARSINOMA UROTHELIAL
by: Ananta Cahyo Nugroho, NIM01131896305
Published: (2018)

Clonal relationship of synchronous head and neck cancer and esophageal cancer assessed by single nucleotide polymorphism-based loss of heterozygosity analysis
by: Somkiat Sunpaweravong, et al.
Published: (2020)

First-Line Pemetrexed Plus Cisplatin Followed by Gefitinib Maintenance Therapy Versus Gefitinib Monotherapy in East Asian Never-Smoker Patients with Locally Advanced or Metastatic Nonsquamous Non-Small-cell Lung Cancer: Quality of Life Results from a Randomized Phase III Trial
by: Mark Boye, et al.
Published: (2018)

Fatal cystic change of brain metastasis after response to gefitinib in non-small-cell lung cancer
by: Zee, Y.-K., et al.
Published: (2014)

Ring-Opened Adducts of the Anticancer Drug Carboplatin with Sulfur Amino Acids
by: Barnham, K.J., et al.
Published: (2014)

Adverse affects of paclitaxel and carboplatin combination chemotherapy in epithelial gynecologic cancer
by: Kietpeerakool C., et al.
Published: (2014)

Adverse affects of paclitaxel and carboplatin combination chemotherapy in epithelial gynecologic cancer
by: Chumnan Kietpeerakool, et al.
Published: (2018)